Meetings - The ASCO Post

This is Part 3 of Next-Generation Therapies for Metastatic Hormone Receptor–Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos fr...

breast cancer

/ Next-Generation Therapies for Metastatic HR-Positive Breast Cancer

PIK3CA-Mutated Metastatic Breast Cancer

This is Part 2 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundt...

breast cancer

/ Next-Generation Therapies for Metastatic HR-Positive Breast Cancer

ESR1-Mutated Metastatic Breast Cancer

This is Part 1 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundt...

Next-Generation Therapies for Metastatic HR-Positive Breast Cancer

Endocrine-Resistant Metastatic Breast Cancer

PIK3CA-Mutated Metastatic Breast Cancer

ESR1-Mutated Metastatic Breast Cancer

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma